Loading...
Loading...
CALT| Name | Value |
|---|---|
| Revenues | 191.4M |
| Cost of Revenue | 9.0M |
| Gross Profit | 182.3M |
| Operating Expense | 366.4M |
| Operating I/L | -184.1M |
| Other Income/Expense | -27.9M |
| Interest Income | 27.9M |
| Pretax | -208.0M |
| Income Tax Expense | -20.5M |
| Net Income/Loss | -187.5M |
Calliditas Therapeutics AB (publ) is a clinical-stage biopharmaceutical company specializing in identifying, developing, and commercializing pharmaceutical products for orphan indications, with a focus on renal and hepatic diseases. Its flagship product, Nefecon, is an oral formulation of budesonide used as an immunosuppressant for treating immunoglobulin A nephropathy. The company's lead product candidate, Setanaxib, is a NOX inhibitor undergoing Phase 2b/3 clinical trials for primary biliary cholangitis and Phase 2 trials for squamous cell carcinoma of the head and neck cancer, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, Calliditas Therapeutics AB develops Budenofalk 3 mg oral capsules for autoimmune hepatitis treatment.
